Ammar Sukari

6.8k total citations · 2 hit papers
118 papers, 2.3k citations indexed

About

Ammar Sukari is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Otorhinolaryngology. According to data from OpenAlex, Ammar Sukari has authored 118 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 51 papers in Pulmonary and Respiratory Medicine and 30 papers in Otorhinolaryngology. Recurrent topics in Ammar Sukari's work include Cancer Immunotherapy and Biomarkers (41 papers), Lung Cancer Treatments and Mutations (36 papers) and Head and Neck Cancer Studies (30 papers). Ammar Sukari is often cited by papers focused on Cancer Immunotherapy and Biomarkers (41 papers), Lung Cancer Treatments and Mutations (36 papers) and Head and Neck Cancer Studies (30 papers). Ammar Sukari collaborates with scholars based in United States, Japan and Spain. Ammar Sukari's co-authors include Misako Nagasaka, Asfar S. Azmi, Sai‐Hong Ignatius Ou, Mohammed Najeeb Al Hallak, Nabil F. Saba, Tanguy Y. Seiwert, Stephen V. Liu, Francis P. Worden, Lori J. Wirth and Michael K. Gibson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Ammar Sukari

112 papers receiving 2.3k citations

Hit Papers

Pembrolizumab for Platinum- and Cetuximab-Refractory Head... 2017 2026 2020 2023 2017 2024 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
    2017 497 citations Joshua Bauml, Tanguy Y. Seiwert et al. Journal of Clinical Oncology profile →
  2. Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors
    2024 62 citations Adam J. Schoenfeld, Sylvia M. Lee et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ammar Sukari United States 24 1.5k 640 635 381 372 118 2.3k
Nicole G. Chau United States 24 1.3k 0.8× 640 1.0× 449 0.7× 193 0.5× 495 1.3× 80 2.3k
Meredith A. Goldwasser United States 17 1.4k 0.9× 875 1.4× 969 1.5× 176 0.5× 670 1.8× 29 2.7k
Caroline Even France 22 1.8k 1.2× 332 0.5× 812 1.3× 411 1.1× 853 2.3× 142 2.5k
Shaodong Hong China 28 2.9k 1.9× 619 1.0× 1.8k 2.9× 542 1.4× 310 0.8× 128 3.9k
Hyunseok Kang United States 28 2.0k 1.3× 772 1.2× 889 1.4× 336 0.9× 1.0k 2.7× 102 3.4k
Paolo Muto Italy 21 789 0.5× 387 0.6× 664 1.0× 191 0.5× 185 0.5× 117 1.7k
Laura Pala Italy 18 1.3k 0.9× 348 0.5× 523 0.8× 525 1.4× 82 0.2× 66 2.1k
Jared Weiss United States 24 1.1k 0.7× 430 0.7× 1.1k 1.7× 89 0.2× 730 2.0× 104 2.2k
Stefan Kasper Germany 24 885 0.6× 636 1.0× 397 0.6× 448 1.2× 110 0.3× 122 2.0k
Wen‐Wei Sung Taiwan 20 630 0.4× 580 0.9× 371 0.6× 190 0.5× 92 0.2× 91 1.5k

Countries citing papers authored by Ammar Sukari

Since Specialization
Citations

This map shows the geographic impact of Ammar Sukari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ammar Sukari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ammar Sukari more than expected).

Fields of papers citing papers by Ammar Sukari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ammar Sukari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ammar Sukari. The network helps show where Ammar Sukari may publish in the future.

Co-authorship network of co-authors of Ammar Sukari

This figure shows the co-authorship network connecting the top 25 collaborators of Ammar Sukari. A scholar is included among the top collaborators of Ammar Sukari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ammar Sukari. Ammar Sukari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yassin, Ahmed, et al.. (2025). Tongue Squamous Cell Carcinoma With Cardiac Metastases. JACC Case Reports. 30(1). 102846–102846. 1 indexed citations
2.
Bourhis, Jean, Lisa Licitra, Barbara Burtness, et al.. (2025). Xevinapant or Placebo Plus Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck (TrilynX): A Randomized, Phase III Study. Journal of Clinical Oncology. 43(29). 3209–3220. 2 indexed citations
3.
Ferris, Robert L., Rom S. Leidner, Christine H. Chung, et al.. (2025). Efficacy and safety of one-time autologous tumor-infiltrating lymphocyte cell therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Journal for ImmunoTherapy of Cancer. 13(8). e011633–e011633. 1 indexed citations
4.
Luo, Jia, Mark G. Evans, Tolulope Adeyelu, et al.. (2024). Multiomic Characterization and Molecular Profiling of Nuclear Protein in Testis Carcinoma. JCO Precision Oncology. 8(8). e2400334–e2400334. 2 indexed citations
5.
Schoenfeld, Adam J., Sylvia M. Lee, Scott Gettinger, et al.. (2024). Lifileucel, an Autologous Tumor-Infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non–Small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors. Cancer Discovery. 14(8). 1389–1402. 62 indexed citations breakdown →
6.
Hanna, Glenn J., Punita Grover, Andrew Elliott, et al.. (2024). Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II. Clinical Cancer Research. 30(10). 2225–2232. 6 indexed citations
7.
Aggarwal, Charu, Nabil F. Saba, Alain P. Algazi, et al.. (2022). Safety and Efficacy of MEDI0457 plus Durvalumab in Patients with Human Papillomavirus–Associated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma. Clinical Cancer Research. 29(3). 560–570. 26 indexed citations
8.
Kim, Seongho, John D. Cramer, S. Naweed Raza, et al.. (2022). African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer. Head & Neck. 44(10). 2069–2076. 4 indexed citations
9.
Ibrahim, Mohamad Nasir Mohamad, et al.. (2022). Femoral metastasis in previously treated bladder cancer patient: A case report. SHILAP Revista de lepidopterología. 10(9). e6357–e6357. 2 indexed citations
10.
Deneka, Alexander Y., Yasmine Baca, Ilya G. Serebriiskii, et al.. (2022). Association of T P53 and CDKN2A Mutation Profile with Tumor Mutation Burden in Head and Neck Cancer. Clinical Cancer Research. 28(9). 1925–1937. 40 indexed citations
11.
12.
Azar, Ibrahim, et al.. (2021). Spotlight on Trastuzumab Deruxtecan (DS-8201,T-DXd) for HER2 Mutation Positive Non-Small Cell Lung Cancer. SHILAP Revista de lepidopterología. Volume 12. 103–114. 22 indexed citations
13.
14.
Nagasaka, Misako, Md. Hafiz Uddin, Mohammed Najeeb Al Hallak, et al.. (2021). Liquid biopsy for therapy monitoring in early-stage non-small cell lung cancer. Molecular Cancer. 20(1). 82–82. 85 indexed citations
15.
Nagasaka, Misako, et al.. (2020). A user’s guide to lorlatinib. Critical Reviews in Oncology/Hematology. 151. 102969–102969. 33 indexed citations
16.
Nagasaka, Misako, Yiwei Li, Ammar Sukari, et al.. (2020). KRAS G12C Game of Thrones, which direct KRAS inhibitor will claim the iron throne?. Cancer Treatment Reviews. 84. 101974–101974. 147 indexed citations
17.
Nagasaka, Misako, Nadine Abdallah, Dhaval Patel, et al.. (2019). <p>A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors</p>. SHILAP Revista de lepidopterología. Volume 10. 95–105. 5 indexed citations
18.
Nagasaka, Misako, et al.. (2019). Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer—A review. Critical Reviews in Oncology/Hematology. 145. 102841–102841. 36 indexed citations
19.
Khan, Husain Yar, Misako Nagasaka, Amro Aboukameel, et al.. (2019). Targeting XPO1 and PAK4 in 8505C Anaplastic Thyroid Cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance. International Journal of Molecular Sciences. 21(1). 237–237. 30 indexed citations
20.
Bauml, Joshua, Tanguy Y. Seiwert, David G. Pfister, et al.. (2017). Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Journal of Clinical Oncology. 35(14). 1542–1549. 497 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Nicole G. Chau Breakdown of academic impact, for papers by Meredith A. Goldwasser Breakdown of academic impact, for papers by Caroline Even Breakdown of academic impact, for papers by Shaodong Hong Breakdown of academic impact, for papers by Hyunseok Kang Breakdown of academic impact, for papers by Paolo Muto Breakdown of academic impact, for papers by Laura Pala Breakdown of academic impact, for papers by Jared Weiss Breakdown of academic impact, for papers by Stefan Kasper Breakdown of academic impact, for papers by Wen‐Wei Sung
Rankless by CCL
2026